Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF

Journal of Immunology

Volumn 191, Issue 12, 2013, Pages 6241-6249

  Lundqvist, Andreas ^a,b   Smith, Aleah L ^a   Takahashi, Yoshiyuki ^c   Wong, Susan ^a   Bahceci, Erkut ^d   Cook, Lisa ^a   Ramos, Catalina ^a   Tawab, Abdul ^e   McCoy Jr , J Philip ^a   Read, Elizabeth J ^e   Khuu, Hanh M ^e   Bolan, Charles D ^e   Joo, Jungnam ^e   Geller, Nancy ^e   Leitman, Susan F ^e   Calandra, Gary ^f   Dunbar, Cynthia ^a   Kurlander, Roger ^e   Childs, Richard W ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Sanofi Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; L SELECTIN; PLERIXAFOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOWN REGULATION; FEMALE; FOXP3 GENE; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOPHENOTYPING; INCIDENCE; MALE; MIDDLE AGED; MINOR HISTOCOMPATIBILITY COMPLEX; NORMAL HUMAN; PHENOTYPIC VARIATION; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL MOBILIZATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TH3 CELL; YOUNG ADULT;

EID: 84890413004     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301148     Document Type: Article

References (45)

1. Larochelle, A., A. Krouse, M. Metzger, D. Orlic, R. E. Donahue, S. Fricker, G. Bridger, C. E. Dunbar, and P. Hematti. 2006. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107: 3772-3778.
2. Moncada, V., C. Bolan, Y. Y. Yau, and S. F. Leitman. 2003. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 43: 495-501.
3. Martínez, C., A. Urbano-Ispizua, P. Marín, A. Merino, M. Rovira, E. Carreras, and E. Montserrat. 1999. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 24: 1273-1278.
4. Champlin, R. E., N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza, Jr., B. Hertenstein, et al IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). 2000. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95: 3702-3709.
5. Mielcarek, M., and B. Torok-Storb. 1997. Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells. Curr. Opin. Hematol. 4: 176-182.
6. Couban, S., D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al Canadian Bone Marrow Transplant Group. 2002. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100: 1525-1531.
7. Bensinger, W. I., P. J. Martin, B. Storer, R. Clift, S. J. Forman, R. Negrin, A. Kashyap, M. E. Flowers, K. Lilleby, T. R. Chauncey, et al. 2001. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344: 175-181.
8. Powles, R., J. Mehta, S. Kulkarni, J. Treleaven, B. Millar, J. Marsden, V. Shepherd, A. Rowland, B. Sirohi, D. Tait, et al. 2000. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 355: 1231-1237.
9. Blaise, D., M. Kuentz, C. Fortanier, J. H. Bourhis, N. Milpied, L. Sutton, J. P. Jouet, M. Attal, P. Bordigoni, J. Y. Cahn, et al. 2000. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J. Clin. Oncol. 18: 537-546.
10. Vigorito, A. C., W. M. Azevedo, J. F. Marques, A. M. Azevedo, K. A. Eid, F. J. Aranha, I. Lorand-Metze, G. B. Oliveira, M. E. Correa, A. R. Reis, et al. 1998. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 22: 1145-1151.
11. Klangsinsirikul, P., and N. H. Russell. 2002. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp. Hematol. 30: 495-501.
12. Sloand, E. M., S. Kim, J. P. Maciejewski, F. Van Rhee, A. Chaudhuri, J. Barrett, and N. S. Young. 2000. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95: 2269-2274.
13. Pan, L., J. Delmonte, Jr., C. K. Jalonen, and J. L. Ferrara. 1995. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86: 4422-4429.
14. Hartung, T., W. D. Döcke, F. Gantner, G. Krieger, A. Sauer, P. Stevens, H. D. Volk, and A. Wendel. 1995. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85: 2482-2489.
15. Schols, D., J. A. Esté, G. Henson, and E. De Clercq. 1997. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35: 147-156.
16. Hatse, S., K. Princen, G. Bridger, E. De Clercq, and D. Schols. 2002. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527: 255-262.
17. Peled, A., I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, A. Nagler, H. Ben-Hur, A. Many, L. Shultz, et al. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283: 845-848.
18. Kollet, O., A. Spiegel, A. Peled, I. Petit, T. Byk, R. Hershkoviz, E. Guetta, G. Barkai, A. Nagler, and T. Lapidot. 2001. Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood 97: 3283-3291.
19. Liles, W. C., H. E. Broxmeyer, E. Rodger, K. Hubel, S. Cooper, G. Hangoc, G. Bridger, G. Henson, G. Calandra, and D. C. Dale. 2001. Leucocytosis and mobilization of pluripotent hematopoietic progenitor cells in healthy volunteers induced by single dose administration of AMD-3100, a CXCR4 antagonist. Blood 98: 737a.
20. Liles, W. C., H. E. Broxmeyer, E. Rodger, B. Wood, K. Hübel, S. Cooper, G. Hangoc, G. J. Bridger, G. W. Henson, G. Calandra, and D. C. Dale. 2003. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728-2730.
21. Devine, S. M., R. Vij, M. Rettig, L. Todt, K. McGlauchlen, N. Fisher, H. Devine, D. C. Link, G. Calandra, G. Bridger, et al. 2008. Rapid mobilization of functional donor hematopoietic cells without G-CSF using plerixafor, an antagonist of the CXCR4/SDF-1 interaction. Blood.
22. Devine, S. M., L. Andritsos, L. Todt, R. Vij, J. Bonde, D. Hess, J. Nolta, D. Link, G. Bridger, G. Calandra, and J. F. Dipersio. 2005. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood 106: 91A.
23. Kang, E. M., E. M. Areman, V. David-Ocampo, C. Fitzhugh, M. E. Link, E. J. Read, S. F. Leitman, G. P. Rodgers, and J. F. Tisdale. 2002. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 99: 850-855.
24. Kammula, U. S., K. H. Lee, A. I. Riker, E. Wang, G. A. Ohnmacht, S. A. Rosenberg, and F. M. Marincola. 1999. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163: 6867-6875.
25. Schnopp, C., R. Rad, A. Weidinger, S. Weidinger, J. Ring, B. Eberlein, M. Ollert, and M. Mempel. 2007. Fox-P3-positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium-dose UVA1 therapy. Photodermatol. Photoimmunol. Photomed. 23: 81-85.
26. Lundqvist, A., J. P. McCoy, L. Samsel, and R. Childs. 2007. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 109: 3603-3606.
27. Yang, H., and G. Churchill. 2007. Estimating p-values in small microarray experiments. Bioinformatics 23: 38-43.
28. Storey, J. 2002. A direct approach to false discovery rate. J. R. Stat. Soc. Ser. A Stat. Soc. 46: 479-498.
29. Miura, Y., C. J. Thoburn, E. C. Bright, M. L. Phelps, T. Shin, E. C. Matsui, W. H. Matsui, S. Arai, E. J. Fuchs, G. B. Vogelsang, et al. 2004. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104: 2187-2193.
30. Sugimori, N., S. Nakao, A. Yachie, T. Niki, A. Takami, H. Yamazaki, Y. Miura, M. Ueda, S. Shiobara, and T. Matsuda. 1999. Administration of G-CSF to normal individuals diminishes L-selectin+ T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin- T cells. Bone Marrow Transplant. 23: 119-124.
31. Anderson, B. E., J. McNiff, J. Yan, H. Doyle, M. Mamula, M. J. Shlomchik, and W. D. Shlomchik. 2003. Memory CD4+ T cells do not induce graft-versus-host disease. J. Clin. Invest. 112: 101-108.
32. Arslan, O., H. Akan, M. Arat, K. Dalva, M. Ozcan, G. Gürman, O. Ilhan, N. Konuk, M. Beksaç, A. Uysal, and H. Koç. 2000. Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF. Cytotherapy 2: 259-265.
33. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1: 433-440.
34. Polak, M. E., L. Newell, V. Y. Taraban, C. Pickard, E. Healy, P. S. Friedmann, A. Al-Shamkhani, and M. R. Ardern-Jones. 2012. CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. J. Invest. Dermatol. 132: 1636-1644.
35. Hübel, K., G. Mansmann, H. Schäfer, F. Oberhäuser, V. Diehl, and A. Engert. 2000. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Cytokine 12: 1797-1800.
36. Gesser, B., M. Lund, N. Lohse, C. Vestergaad, K. Matsushima, S. Sindet-Pedersen, S. L. Jensen, K. Thestrup-Pedersen, and C. G. Larsen. 1996. IL-8 induces T cell chemotaxis, suppresses IL-4, and up-regulates IL-8 production by CD4+ T cells. J. Leukoc. Biol. 59: 407-411.
37. Franzke, A., W. Piao, J. Lauber, P. Gatzlaff, C. Könecke, W. Hansen, A. Schmitt-Thomsen, B. Hertenstein, J. Buer, and A. Ganser. 2003. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 102: 734-739.
38. Joo, Y. D., W. S. Lee, H. J. Won, S. M. Lee, H. R. Kim, J. K. Park, S. G. Park, I. W. Choi, I. Choi, and S. K. Seo. 2012. G-CSF-treated donor CD4+ T cells attenuate acute GVHD through a reduction in Th17 cell differentiation. Cytokine 60: 277-283.
39. Pabst, C., H. Schirutschke, G. Ehninger, M. Bornhäuser, and U. Platzbecker. 2007. The graft content of donor T cells expressing gamma delta TCR+ and CD4+ foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin. Cancer Res. 13: 2916-2922.
40. Rezvani, K., S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, and A. J. Barrett. 2006. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108: 1291-1297.
41. Wolf, D., A. M. Wolf, D. Fong, H. Rumpold, A. Strasak, J. Clausen, and D. Nachbaur. 2007. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 83: 1107-1113.
42. Edinger, M., P. Hoffmann, J. Ermann, K. Drago, C. G. Fathman, S. Strober, and R. S. Negrin. 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
43. Di Ianni, M., F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. Ostini, D. Cecchini, et al. 2011. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117: 3921-3928.
44. Zorn, E., H. T. Kim, S. J. Lee, B. H. Floyd, D. Litsa, S. Arumugarajah, R. Bellucci, E. P. Alyea, J. H. Antin, R. J. Soiffer, and J. Ritz. 2005. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106: 2903-2911.
45. Devine, S. M., R. Vij, M. Rettig, L. Todt, K. McGlauchlen, N. Fisher, H. Devine, D. C. Link, G. Calandra, G. Bridger, et al. 2008. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112: 990-998.